Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pomalidomide Celgene

- PMLiVE

Celgene wins EU pancreatic cancer approval for Abraxane

Adds to drug's existing breast cancer indication

Novartis building

Novartis myeloma drug clears phase III trial

Panobinostat on course to be first in new class of treatment for bone marrow cancer

- PMLiVE

Celgene signs $3.3bn cancer deal with OncoMed

Includes lead candidate demcizumab

- PMLiVE

Revlimid performance leads Celgene to trio of PMEAs

Wins Small Company of the Year thanks to work on rare cancer drug

National Institute for Health and Care Excellence NICE logo

NICE denies early use of Janssen’s Velcade

Draft guidance doesn't recommend expanded bone marrow cancer indication

Celgene poaches Sanofi Pasteur’s medical director

Adrian Kilcoyne announced as David Gillen’s replacement

- PMLiVE

Celgene lifted by apremilast data in psoriatic arthritis

Long-term data keeps marketing application plans on course

- PMLiVE

Celgene’s Revlimid knocked-back by NICE

Final draft guidance from NICE does not recommend drug for rare bone marrow disorder

- PMLiVE

Janssen buys hepatitis C candidate from GSK

J&J subsidiary acquires rights to NS5A inhibitor

Actelion HQ Switzerland

Actelion complete Ceptaris purchase

Follows approval of lymphoma gel product Valchlor

Bristol-Myers Squibb (BMS) building

BMS says it defends Sprycel patent in India

Blocks attempts to issue compulsory license for leukaemia drug

- PMLiVE

J&J hit by more recalls

Withdraws 200,000 bottles of cough drops in US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links